Eagle May Launch Vasopressin ‘At-Risk’ As January Trial Looms

Additional Complex ANDAs Could Be On The Radar

 
• By Dean Rudge

Eagle Pharmaceuticals is looking increasingly likely to launch its generic of Endo’s $700m Vasostrict (vasopressin) injectable ‘at risk’ amid FDA priority review for its ANDA and a delayed trial on Vasostrict intellectual property, set to take place in January next year.

Eagle flying set against the sky
'We’re very willing partners and very good partners,' Eagle said of its complex ANDA strategy • Source: Shutterstock

More from Generics

More from Products